跳至主要内容
临床试验/DRKS00023991
DRKS00023991已完成不适用

Quality of life and late effects in leukemia survivors - AML SURVIVORSHIP

Medizinische Klinik IUniversitätsklinikum Leipzig0 个研究点目标入组 427 人开始时间: 2021年1月6日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
427

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Patients suffering from acute myeloid leukemia (AML) who were enrolled into the patient registry of the German AML Cooperative Group (AML-CG, DRKS00020816) and/or one of the following interventional trials: AMLCG-1999 (clinicaltrials.gov NCT00266136), AMLCG-2004 (European Leukemia Trial Registry Nr. LN_AMLINT_2004_230), AMLCG-2008 (clinicaltrials.gov NCT01382147).
  • - Study participants have survived =5 years from initial diagnosis off AML.

排除标准

  • - Current leukemia relapse
  • - Age <18 years
  • - Inability to give valid informed consent
  • - Insufficient german language proficiency which makes the participant unable to answer the study questionnaires

研究者

发起方
Medizinische Klinik IUniversitätsklinikum Leipzig

相似试验